AIIMS-Delhi begins screening children for COVAXIN clinical trials from today

·3-min read


AIIMS-Delhi begins screening children for COVAXIN clinical trials from today
AIIMS-Delhi begins screening children for COVAXIN clinical trials from today

07 Jun 2021: AIIMS-Delhi begins screening children for COVAXIN clinical trials from today

The All India Institute of Medical Sciences (AIIMS), Delhi will begin screening children from Monday to conduct clinical trials of the indigenously developed, Bharat Biotech's vaccine against COVID-19, COVAXIN. The clinical trials are crucial to determine if this vaccine is suitable for those aged between two to 18 years. Notably, last week, AIIMS-Patna had already begun COVAXIN clinical trials on children. Here's more.

Crucial: Vaccination of children essential to prepare for possible third wave

The development comes amid experts' warnings of a possible third COVID-19 wave in India during which children are more likely to get infected. Experts say the first wave affected older people, while in the ongoing second wave, youngsters are getting more infected; the third wave could be dangerous for children. Hence, ensuring vaccination of children is crucial to deal with the third wave.

Approval: None of vaccines in use in India approved for children

While India is administering COVAXIN, Covishield, and Sputnik V as part of its vaccination drive, none of these are approved yet for children. However, the Drugs Controller General of India (DCGI) last month approved Bharat Biotech to conduct COVAXIN Phase 2/3 trials on children, followed by a recommendation by the Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO).

Trials: Trials to be conducted on 525 subjects across India

The COVAXIN Phase 2/3 trials would be conducted on 525 subjects aged between two and 18 years. The two-dose vaccine will be administered 28 days apart. The trials would be held across numerous sites, including AIIMS-Delhi, AIIMS-Patna, ESI Hospital, Basaidarapur (Delhi); Prakhar Hospital, Kanpur; Mysore Medical College and Research Institute, Mysuru; Pranaam Hospital, Hyderabad; and Meditrina Institute of Medical Sciences, Nagpur, beginning this month.

AIIMS-Patna: Clinical trials on children at AIIMS-Patna began on June 3

To recall, AIIMS-Patna had begun the Phase 2/3 clinical trials of COVAXIN on children on June 3. Dr. CM Singh, AIIMS-Patna Superintendent and the Principal Investigator of the trials, said these clinical trials will be conducted in the reverse order of age: the 12-18 years age group will be inoculated first followed by the 6-12 years and 2-6 years age brackets.

Other countries: What about vaccines approved for children in other countries?

While India is yet to approve a vaccine for children, several countries like the US, the UK, and Canada have authorized vaccines for some age groups. The US, the UK, and Canada cleared Pfizer-BioNTech's vaccine for those aged 12-15 years, while China recently authorized the use of Sinovac's CoronaVac for children aged 3-17 years. However, most countries are yet to immunize kids against COVID-19.

COVID-19 situation: India witnesses lowest single-day spike in cases in two months

Meanwhile, many states in India have started preparing for the expected third wave, focusing on strengthening healthcare infrastructure, especially for children; several states are also setting up Pediatric Intensive Care Units (PICUs). On the other hand, the COVID-19 situation in India seems to be improving gradually. On Monday, the country reported 100,636 cases in the last 24 hours—the lowest single-day spike in two months.

The news article, AIIMS-Delhi begins screening children for COVAXIN clinical trials from today appeared first on NewsBytes.

Also see: COVAXIN trials on children aged 2-18 begin at AIIMS-Patna
COVAXIN trials on children are expected to begin in June
COVAXIN phase 2/3 trials for 2-18-year-olds recommended by expert panel
Read more on India by NewsBytes.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting